Molecular control of cell cycle progression in primary human hematopoietic stem cells: Methods to increase levels of retroviral-mediated transduction

M. A. Dao, Jan Nolta

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Pluripotent hematopoietic stem cells (HSC) are the ideal targets for gene transfer because they can repopulate a sublethally irradiated recipient, giving rise to all lineages of blood cells. Thus, introduction of a corrected gene into HSC (stem cell gene therapy) should ensure persistent transmission of the gene. To date, the most efficient mode of gene delivery is via Moloney murine leukemia virus (MoMuLV)-based retroviral vectors which stably integrate into the genome of the target cell. The quiescent nature of HSC and the fact that MoMuLV-based retroviral vectors can only integrate into dividing cells are major obstacles in gene therapy. While increasing efforts have been directed toward identifying growth factors which facilitate division of primary hematopoietic progenitor and stem cells, little is known about the molecular mechanisms which these cells use to enter cell cycle. In this review, we will discuss the correlation between the hematopoietic inhibitory and growth factors and their impact on the regulation of the cell cycle components.

Original languageEnglish (US)
Pages (from-to)1473-1480
Number of pages8
JournalLeukemia
Volume13
Issue number10
StatePublished - 1999
Externally publishedYes

Fingerprint

Hematopoietic Stem Cells
Cell Cycle Checkpoints
Moloney murine leukemia virus
Genetic Therapy
Genes
Cell Cycle
Pluripotent Stem Cells
Cellular Structures
Cell- and Tissue-Based Therapy
Blood Cells
Intercellular Signaling Peptides and Proteins
Stem Cells
Genome

Keywords

  • CDK inhibitors
  • Cell cycle
  • Hematopoietic stem cells
  • p27 kip-1
  • Retroviral-mediated transduction

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

@article{032cab19e35f4f7c9ffcd2fbfe850b2f,
title = "Molecular control of cell cycle progression in primary human hematopoietic stem cells: Methods to increase levels of retroviral-mediated transduction",
abstract = "Pluripotent hematopoietic stem cells (HSC) are the ideal targets for gene transfer because they can repopulate a sublethally irradiated recipient, giving rise to all lineages of blood cells. Thus, introduction of a corrected gene into HSC (stem cell gene therapy) should ensure persistent transmission of the gene. To date, the most efficient mode of gene delivery is via Moloney murine leukemia virus (MoMuLV)-based retroviral vectors which stably integrate into the genome of the target cell. The quiescent nature of HSC and the fact that MoMuLV-based retroviral vectors can only integrate into dividing cells are major obstacles in gene therapy. While increasing efforts have been directed toward identifying growth factors which facilitate division of primary hematopoietic progenitor and stem cells, little is known about the molecular mechanisms which these cells use to enter cell cycle. In this review, we will discuss the correlation between the hematopoietic inhibitory and growth factors and their impact on the regulation of the cell cycle components.",
keywords = "CDK inhibitors, Cell cycle, Hematopoietic stem cells, p27 kip-1, Retroviral-mediated transduction",
author = "Dao, {M. A.} and Jan Nolta",
year = "1999",
language = "English (US)",
volume = "13",
pages = "1473--1480",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Molecular control of cell cycle progression in primary human hematopoietic stem cells

T2 - Methods to increase levels of retroviral-mediated transduction

AU - Dao, M. A.

AU - Nolta, Jan

PY - 1999

Y1 - 1999

N2 - Pluripotent hematopoietic stem cells (HSC) are the ideal targets for gene transfer because they can repopulate a sublethally irradiated recipient, giving rise to all lineages of blood cells. Thus, introduction of a corrected gene into HSC (stem cell gene therapy) should ensure persistent transmission of the gene. To date, the most efficient mode of gene delivery is via Moloney murine leukemia virus (MoMuLV)-based retroviral vectors which stably integrate into the genome of the target cell. The quiescent nature of HSC and the fact that MoMuLV-based retroviral vectors can only integrate into dividing cells are major obstacles in gene therapy. While increasing efforts have been directed toward identifying growth factors which facilitate division of primary hematopoietic progenitor and stem cells, little is known about the molecular mechanisms which these cells use to enter cell cycle. In this review, we will discuss the correlation between the hematopoietic inhibitory and growth factors and their impact on the regulation of the cell cycle components.

AB - Pluripotent hematopoietic stem cells (HSC) are the ideal targets for gene transfer because they can repopulate a sublethally irradiated recipient, giving rise to all lineages of blood cells. Thus, introduction of a corrected gene into HSC (stem cell gene therapy) should ensure persistent transmission of the gene. To date, the most efficient mode of gene delivery is via Moloney murine leukemia virus (MoMuLV)-based retroviral vectors which stably integrate into the genome of the target cell. The quiescent nature of HSC and the fact that MoMuLV-based retroviral vectors can only integrate into dividing cells are major obstacles in gene therapy. While increasing efforts have been directed toward identifying growth factors which facilitate division of primary hematopoietic progenitor and stem cells, little is known about the molecular mechanisms which these cells use to enter cell cycle. In this review, we will discuss the correlation between the hematopoietic inhibitory and growth factors and their impact on the regulation of the cell cycle components.

KW - CDK inhibitors

KW - Cell cycle

KW - Hematopoietic stem cells

KW - p27 kip-1

KW - Retroviral-mediated transduction

UR - http://www.scopus.com/inward/record.url?scp=0032830032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032830032&partnerID=8YFLogxK

M3 - Article

C2 - 10516745

AN - SCOPUS:0032830032

VL - 13

SP - 1473

EP - 1480

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 10

ER -